The University of Texas System

Dnatrix, Inc.

Other

Regeneron Pharmaceuticals, Inc.

The Uab Research Foundation (the University of Alabama at Birmingham)

Candelaria Gomez-Manzano

Charles A Conrad

W K Alfred Yung

Juan Fueyo-Margareto

Juan Fueyo

Frederick Lang, Jr

Frank Tufaro

Amy Heimberger

Hong Jiang

Wk Alfred Yung

David T Curiel

Jesse M Cedarbaum

Jocelyn Holash

Victor Krasnykh

The present invention is directed to adenoviruses for use in cancer therapy which comprise one or more heterologous nucleic acid sequences encoding a tumor antigen, whereby the adenovirus expresses the tumor antigen(s) on its surface.

Adenoviruses expressing heterologous tumor-associated antigens

Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.

Adenovirus and immunomodulator combination therapy

The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.

Biomarkers and combination therapies using oncolytic virus and immunomodulation

A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.

Infectivity-enhanced conditionally-replicative adenovirus and uses thereof

The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.

Oncolytic adenovirus armed with therapeutic genes

Methods for treating a human patient suffering from a brain tumor, including glioblastoma, by administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human patient. The VEGF inhibitor is a VEGF antagonist protein comprising a dimeric protein having two fusion polypeptides having the sequence of SEQ ID NO:2.

Use of VEGF antagonists for the treatment of malignant gliomas

Growing community of inventors

Houston, TX, United States of America

Candelaria Gomez-Manzano